Liver-on-chips for drug discovery and development
Year: 2024
Type: review
Abstract: Recent FDA modernization act 2.0 has led to increasing industrial R&D investment in advanced in vitro 3D models such as organoids, spheroids, organ-on-chips, 3D bioprinting, and in silico approaches. Liver-related advanced in vitro models remain the prime area of interest, as liver plays a central role in drug clearance of compounds. Growing evidence indicates the importance of recapitulating the overall liver microenvironment to enhance hepatocyte maturity and culture longevity using liver-on-chips (LoC) in vitro. Hence, pharmaceutical industries have started exploring LoC assays in the two of the most challenging areas: accurate in vitro-in vivo extrapolation (IVIVE) of hepatic drug clearance and drug-induced liver injury. We examine the joint efforts of commercial chip manufacturers and pharmaceutical companies to present an up-to-date overview of the adoption of LoC technology in the drug discovery. Further, several roadblocks are identified to the rapid adoption of LoC assays in the current drug development framework. Finally, we discuss some of the underexplored application areas of LoC models, where conventional 2D hepatic models are deemed unsuitable. These include clearance prediction of metabolically stable compounds, immune-mediated drug-induced liver injury (DILI) predictions, bioavailability prediction with gut-liver systems, hepatic clearance prediction of drugs given during pregnancy, and dose adjustment studies in disease conditions. We conclude the review by discussing the importance of PBPK modeling with LoC, digital twins, and AI/ML integration with LoC.
Source: Materials Today Bio
Authors: Viraj Mehta, Guruswamy Karnam, Vamsi Madgula
Language: English
Subfield: Biomedical Engineering
Field: Engineering
Domain: Physical Sciences
Keywords: liver-on-a-chip, organ-on-a-chip, drug discovery, drug-induced liver injury, in vitro-in vivo extrapolation, hepatic clearance, organoids, spheroids, bioavailability prediction, dose adjustment, physiologically based pharmacokinetic modeling, digital twin, artificial intelligence in drug development
Open Access status: gold
Estimated APC paid: $3,150
OpenAlex ID: W4400250553
